Exchange: NASDAQ·Updated 04:36 AM EDT
News
all
press releases
Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of +33.33% and -5.80%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
Akebia Therapeutics, Inc. (AKBA) Strengthens Vafseo Patent Protection Through 2036
Akebia Therapeutics, Inc. (AKBA) Strengthens Vafseo Patent Protection Through 2036...
Yahoo! Finance: News
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -125.56% and -5.20%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Akebia Therapeutics (AKBA) Expected to Announce Quarterly Earnings on Thursday
Akebia Therapeutics (NASDAQ:AKBA) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-akebia-therapeutics-inc-stock...
MarketBeat
United Therapeutics (UTHR) Misses Q1 Earnings and Revenue Estimates
United Therapeutics (UTHR) delivered earnings and revenue surprises of -13.58% and -2.36%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Q32 Bio Gears Up to Report Q1 Earnings: What's in the Cards?
QTTB heads into Q1 earnings with investors eyeing bempikibart updates, as the SIGNAL-AA study progresses with data due in mid-2026.
Zacks
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of +64.71% and +29.20%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Are Options Traders Betting on a Big Move in Akebia Therapeutics Stock?
Investors need to pay close attention to AKBA stock based on the movements in the options market lately.
Zacks
New Strong Sell Stocks for April 28th
EADSY, AKBA and AMTB have been added to the Zacks Rank #5 (Strong Sell) List on April 28, 2026.
Zacks
Akebia Therapeutics (NASDAQ:AKBA) Shares Cross Below Two Hundred Day Moving Average - Here's What Happened
Akebia Therapeutics (NASDAQ:AKBA) Stock Crosses Below 200-Day Moving Average - Should You Sell...
MarketBeat

Advertisement|Remove ads.